Gene Synthesis Firm Sloning Gains $6.8M in European Series E Funding | GenomeWeb
NEW YORK (GenomeWeb News) - Sloning Biotechnology said today it has raised €4.7 million ($6.8 million) in Series E venture financing from one new and several previous investors.
Sloning, based in Puchheim, Germany, plans to use the cash to commercialize its Slonomics gene synthesis business internationally and to expand its Slonomax gene mutant library product line.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.